Systemic Vitamin D Supplementation in Dental Implants Patients

Systemic Vitamin D Supplementation in Menopausal Women With Dental Implants

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02582892

Acronym

VitaminD

Enrollment

135

Registered

2015-10-21

Start date

2012-10-31

Completion date

2015-10-31

Last updated

2015-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Brief summary

Vitamin D plays an essential role in calcium homeostasis and is critical for bone formation and remodeling.

Detailed description

Evidence has demonstrated that vitamin D deficiency plays an important role in dental implants outcomes. Low serum levels of Vitamin D is considered as a risk factor, not only for low mineral bone density but also in other metabolic pathways such as those involved in immune response and chronic inflammatory diseases. There are few studies demonstrating the role that vitamin D deficiency in the etiopathogenesis of oral diseases and the consequences in Dental Implants. Dentists have not yet well understood the importance of a good bone metabolism response for a successful bone regeneration and osseointegration of implants. An insufficient bone response can not guarantee the necessary stability of the implants placed in it, has been one of the biggest problems of implantology. Thus, the aim of this study is to evaluate the efficacy of Systemic vitamin D supplementation in menopausal women cadidates for dental implants.

Interventions

DRUGVit D

20 mg/day

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

3 Months to 5 Years

Healthy volunteers

Yes

Inclusion criteria

\- Menopause patients

Exclusion criteria

* patients with a past history of neurological disorder; * who had received pharmacotherapy for depression within 8 weeks of screening; * who were taking medication known to interfere with Vit D; * who had recent psychiatricor systemic illness; * uncontrolled hypertension (blood pressure \> 160/95mmHg); * unstable cardiovascular disease; * User of psychoactive medications; * alcohol excess consumption abuse.

Design outcomes

Primary

Measure	Time frame	Description
25 OH Serum levels	2 years	VIT D Serum levels

Secondary

Measure	Time frame	Description
Osteoporosis condition	2 years	Densitometry in patients femur bones

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026